HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia - Revision history

Bailey.Glen at 17:23, 3 July 2025

2025-07-03T17:23:21Z

← Older revision		Revision as of 12:23, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:42, 25 May 2025

2025-05-25T21:42:49Z

← Older revision		Revision as of 16:42, 25 May 2025
Line 160:		Line 160:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 230:		Line 230:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 274:		Line 274:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:19, 25 May 2025

2025-05-25T20:19:08Z

← Older revision		Revision as of 15:19, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Atypical chronic myeloid leukaemia, BCR::ABL1-negative
	\|}		\|}

Bailey.Glen at 17:41, 24 March 2025

2025-03-24T17:41:44Z

← Older revision		Revision as of 12:41, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Myelodysplastic/myeloproliferative neoplasm with neutrophilia}}		{{DISPLAYTITLE:Myelodysplastic/myeloproliferative neoplasm with neutrophilia}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Linsheng Zhang, MD, PhD		Linsheng Zhang, MD, PhD

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T13:23:43Z

Removed old template contents

Show changes

Bailey.Glen at 18:54, 10 February 2025

2025-02-10T18:54:18Z

Show changes

Bailey.Glen at 18:26, 10 February 2025

2025-02-10T18:26:15Z

← Older revision		Revision as of 13:26, 10 February 2025
Line 77:		Line 77:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>

	The primary symptoms are related to splenomegaly and blood cell changes like anemia and/or thrombocytopenia<ref name=":1" /><ref name=":3">{{Cite journal\|last=R\|first=Kurzrock\|last2=Ce\|first2=Bueso-Ramos\|last3=H\|first3=Kantarjian\|last4=E\|first4=Freireich\|last5=Sl\|first5=Tucker\|last6=M\|first6=Siciliano\|last7=S\|first7=Pilat\|last8=M\|first8=Talpaz\|date=2001\|title=BCR Rearrangement-Negative Chronic Myelogenous Leukemia Revisited\|url=https://pubmed.ncbi.nlm.nih.gov/11387365/\|language=en\|pmid=11387365}}</ref><ref name=":2" />.		The primary symptoms are related to splenomegaly and blood cell changes like anemia and/or thrombocytopenia<ref name=":1" /><ref name=":3">{{Cite journal\|last=R\|first=Kurzrock\|last2=Ce\|first2=Bueso-Ramos\|last3=H\|first3=Kantarjian\|last4=E\|first4=Freireich\|last5=Sl\|first5=Tucker\|last6=M\|first6=Siciliano\|last7=S\|first7=Pilat\|last8=M\|first8=Talpaz\|date=2001\|title=BCR Rearrangement-Negative Chronic Myelogenous Leukemia Revisited\|url=https://pubmed.ncbi.nlm.nih.gov/11387365/\|language=en\|pmid=11387365}}</ref><ref name=":2" />.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 138:		Line 141:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}</blockquote>

	No specific immunophenotypic characteristics (flow cytometric analysis of blood and bone marrow usually report as normal, except mildly increased myeloblasts in some cases).		No specific immunophenotypic characteristics (flow cytometric analysis of blood and bone marrow usually report as normal, except mildly increased myeloblasts in some cases).

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Chromosomal Rearrangements (Gene Fusions)==		==Chromosomal Rearrangements (Gene Fusions)==
Line 166:		Line 172:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	None.		None.
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>

Line 176:		Line 185:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	Genetic abnormalities and mutations in related genes provide evidence of a clonal process to support a neoplastic process. However, they are not specific for aCML.		Genetic abnormalities and mutations in related genes provide evidence of a clonal process to support a neoplastic process. However, they are not specific for aCML.
Line 191:		Line 200:
	*Increased blasts in blood and/or bone marrow.		*Increased blasts in blood and/or bone marrow.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 239:		Line 251:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Karyotypic abnormalities are reported in as many as 80% of cases.		Karyotypic abnormalities are reported in as many as 80% of cases.
Line 247:		Line 259:
	*Isolated isochromosome 17q rare (most present with features of [[HAEM5:Chronic myelomonocytic leukaemia\|CMML]] instead of aCML).		*Isolated isochromosome 17q rare (most present with features of [[HAEM5:Chronic myelomonocytic leukaemia\|CMML]] instead of aCML).

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 271:		Line 286:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	None.		None.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 310:		Line 328:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 341:		Line 359:
	Mutations in ''TET2, ASXL1, EZH2'' and ''SRSF2'' (overlapping with [[HAEM5:Chronic myelomonocytic leukaemia\|CMML]]) are not uncommon in aCML<ref>{{Cite journal\|last=Faisal\|first=Muhammad\|last2=Stark\|first2=Helge\|last3=Büsche\|first3=Guntram\|last4=Schlue\|first4=Jerome\|last5=Teiken\|first5=Kristin\|last6=Kreipe\|first6=Hans H.\|last7=Lehmann\|first7=Ulrich\|last8=Bartels\|first8=Stephan\|date=2019\|title=Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia\|url=http://doi.wiley.com/10.1002/cam4.1946\|journal=Cancer Medicine\|language=en\|volume=8\|issue=2\|pages=742–750\|doi=10.1002/cam4.1946\|pmc=PMC6382710\|pmid=30635983}}</ref>.		Mutations in ''TET2, ASXL1, EZH2'' and ''SRSF2'' (overlapping with [[HAEM5:Chronic myelomonocytic leukaemia\|CMML]]) are not uncommon in aCML<ref>{{Cite journal\|last=Faisal\|first=Muhammad\|last2=Stark\|first2=Helge\|last3=Büsche\|first3=Guntram\|last4=Schlue\|first4=Jerome\|last5=Teiken\|first5=Kristin\|last6=Kreipe\|first6=Hans H.\|last7=Lehmann\|first7=Ulrich\|last8=Bartels\|first8=Stephan\|date=2019\|title=Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia\|url=http://doi.wiley.com/10.1002/cam4.1946\|journal=Cancer Medicine\|language=en\|volume=8\|issue=2\|pages=742–750\|doi=10.1002/cam4.1946\|pmc=PMC6382710\|pmid=30635983}}</ref>.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 366:		Line 387:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Frequently involved:		Frequently involved:
Line 377:		Line 398:
	*PI3K/AKT and MAPK/ERK (CSF3R)		*PI3K/AKT and MAPK/ERK (CSF3R)

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:17, 6 September 2024

2024-09-06T22:17:37Z

← Older revision		Revision as of 17:17, 6 September 2024
Line 15:		Line 15:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	Myeloid ~~neoplasm~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub~~-~~Classification~~ / ~~Subtype==~~		!Disease
			\|-
	~~[[HAEM4:Myelodysplastic/Myeloproliferative Neoplasms~~ (~~MDS/MPN~~)\|Myelodysplastic/~~Myeloproliferative Neoplasm]]~~		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|Myeloid proliferations and neoplasms
			\|-
			\|Family
			\|Myelodysplastic/myeloproliferative neoplasms
			\|-
			\|Type
			\|N/A
			\|-
			\|Subtype(s)
			\|Myelodysplastic/myeloproliferative neoplasm with neutrophilia
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 22:04, 6 September 2024

2024-09-06T22:04:54Z

Show changes

Bailey.Glen at 19:33, 13 December 2023

2023-12-13T19:33:10Z

← Older revision		Revision as of 14:33, 13 December 2023
Line 6:		Line 6:
	<blockquote class='blockedit'>{{Box-round\|title=HAEM5 Conversion Notes\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]].		<blockquote class='blockedit'>{{Box-round\|title=HAEM5 Conversion Notes\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]].
	}}</blockquote>		}}</blockquote>

			<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>

	==Primary Author(s)*==		==Primary Author(s)*==